We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Alkermes Licenses Technology Platform for Long-Acting Fusion Proteins from Acceleron Pharma

News   Dec 04, 2009

 
Alkermes Licenses Technology Platform for Long-Acting Fusion Proteins from Acceleron Pharma
 
 
 

RELATED ARTICLES

Therapeutic Approach to Tackle African Sleeping Sickness

News

Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Their research revealed a promising strategy to develop a suitable agent. This novel concept could also be employed in the future rational design of drugs for the treatment of other diseases.

READ MORE

Rubicon Alters Autophagy in Animals During Aging

News

Rubicon is a protein factor that suppresses autophagy by controlling a specific step in this pathway. This study found that Rubicon expression levels increased in an age-related manner in worm, fly, and mouse tissues.

READ MORE

Compound Could Help Treat Ovarian Cancer

News

Scientists from the University of Sheffield have discovered a compound that could be more effective in treating certain cancers than standard chemotherapy.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE